Literature DB >> 508551

Pharmacokinetics of pemoline in plasma, saliva and urine following oral administration.

N P Vermeulen, M W Teunissen, D D Breimer.   

Abstract

1 Pemoline concentrations were measured in plasma and saliva following a single oral dose (37.5 or 50.0 mg) to healthy volunteers. In addition urinary excretion rates and cumulative urinary excretion of the parent compound and its oxazolidinedione metabolite were determined. 2 The plasma curves exhibited a mean elimination half-live of 11.0 +/- 1.2 h (n=4). Peak levels were reached at 2.7 +/- 0.6 h (n=4). The saliva concentrations were about 50% lower than the corresponding plasma concentrations during the elimination phase. During the absorption phase irregularities in the saliva to plasma concentration ratios were observed. 3 In urine 47.0 +/- 8.4% of the dose (n=6) administered was excreted as unchanged drug and only 3.7 +/- 0.8% (n=3) as the oxazolidinedione metabolite. Urinary half-lives were slightly shorter than the corresponding plasma half-lives.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508551      PMCID: PMC1429813          DOI: 10.1111/j.1365-2125.1979.tb01026.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  [5-Phenyl-2-imino-4-oxo-oxazolidine, a central stimulant substance].

Authors:  L SCHMIDT
Journal:  Arzneimittelforschung       Date:  1956-08

Review 2.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Gas chromatographic determination of pemoline as 5-phenyl-2,4-oxazolidinedione in human urine.

Authors:  N P Vermeulen; D de Roode; D D Breimer
Journal:  J Chromatogr       Date:  1977-07-21

Review 4.  Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring.

Authors:  B H Dvorchik; E S Vesell
Journal:  Clin Chem       Date:  1976-06       Impact factor: 8.327

5.  Tests of learning and memory with Cylert.

Authors:  G A Talland; M T McGuire
Journal:  Psychopharmacologia       Date:  1967

6.  Effects of pemoline on hyperactive boys.

Authors:  R M Knights; C A Viets
Journal:  Pharmacol Biochem Behav       Date:  1975 Nov-Dec       Impact factor: 3.533

7.  Pemoline and magnesium hydroxide versus pemoline: enhancement of learning and memory of a conditioned avoidance response in rats.

Authors:  N Plotnikoff; P Meekma
Journal:  J Pharm Sci       Date:  1967-02       Impact factor: 3.534

8.  Assay of pemoline in human plasma, saliva and urine by capillary gas chromatography with nitrogen-selective detection.

Authors:  N P Vermeulen; M W Teunissen; D D Breimer
Journal:  J Chromatogr       Date:  1978-09-21
  8 in total
  4 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.

Authors:  C P Collier; S J Soldin; J M Swanson; S M MacLeod; F Weinberg; J G Rochefort
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

3.  Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline.

Authors:  A N Nicholson; B M Stone; M M Jones
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.